Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Abatacept With Methotrexate- Phase IIB

ClinicalTrials.gov ID: NCT00162266

Public ClinicalTrials.gov record NCT00162266. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 1:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IIB, Multi-Center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Clinical Efficacy of Two Different Doses of BMS-188667 Administered Intravenously to Subjects With Active Rheumatoid Arthritis While Receiving Methotrexate

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study was conducted to assess the safety and tolerability of Abatacept combined with Methotrexate in participants with active rheumatoid arthritis (RA). The secondary objectives were to assess efficacy, pharmacodynamic marker activity, and immunogenicity of Abatacept combined with Methotrexate.

Study identification

NCT ID
NCT00162266
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Bristol-Myers Squibb
Industry
Enrollment
524 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2000
Primary completion
Aug 31, 2009
Completion
Aug 31, 2009
Last update posted
May 31, 2012

2000 – 2009

United States locations

U.S. sites
26
U.S. states
16
U.S. cities
26
Facility City State ZIP Site status
Local Institution Birmingham Alabama
Local Institution Huntsville Alabama
Local Institution Long Beach California
Local Institution Highlands Ranch Colorado
Local Institution Largo Florida
Local Institution Titusville Florida
Local Institution West Palm Beach Florida
Local Institution Rome Georgia
Local Institution Chicago Illinois
Local Institution Wichita Kansas
Local Institution Cumberland Maryland
Local Institution Springfield Massachusetts
Local Institution Worcester Massachusetts
Local Institution Duluth Minnesota
Local Institution Lincoln Nebraska
Local Institution Albuquerque New Mexico
Local Institution Los Alamos New Mexico
Local Institution Albany New York
Local Institution Binghamton New York
Local Institution The Bronx New York
Local Institution Portland Oregon
Local Institution Duncansville Pennsylvania
Local Institution Sellersville Pennsylvania
Local Institution Amarillo Texas
Local Institution Austin Texas
Local Institution Dallas Texas

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 31 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00162266, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 31, 2012 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00162266 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →